

# **Difference in Plaque Morphology and Stability in STEMI, NSTEMI- ACS and Stable CAD**

*Akiko Maehara, MD*

*Cardiovascular Research Foundation  
Columbia University Medical Center*

# Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

## Affiliation/Financial Relationship

- Grant/Research Support
- Consulting Fees/Honoraria

## Company



- Boston Scientific, St Jude Medical
- Boston Scientific, OCT Medical Imaging Inc.

# Causes of Coronary Thrombosis




Joner M  
CRT2015

## Lesions with acute thrombi

Rupture






Underlying PIT






Erosion


Underlying FA





Calcified nodule



Plaque fissure



# Subclinical episodes of plaque disruption followed by healing, leading to a chronic, high-grade coronary stenosis.



Burk AP et al. *Circulation* 2001;103:934-940.  
Mann J et al. *Heart* 1999;82:265-268.




# Rupture vs Erosion

Rupture: STEMI presentation in 70%, Erosion: NSTEMI presentation in 60%

	Rupture (n=65)	Erosion (n=50)	P-Value
<b>Pathophysiology</b>	<b>Disruption of fibrous cap</b>	<b>Deficiency of endothelium</b>	
Age	52±10	43±9	<0.0001
Male	89%	74%	0.03
Plaque burden (%)	77±14	71±15	<0.0001
% Necrotic core	38±23	18±24	<0.0001
% Macrophage	3.4±2.8	2.5±2.7	<0.0001
<b>Thrombus age</b>			
Early <1 day	46%	12%	
Lytic 1-3 day	26%	14%	
Infiltrating 4-7 day	19%	28%	
Healing >7day	9%	46%	

Kramer M. et al. JACC 2010; 55; 122-32. Libby P. et al. Eur Heart J 2015; 36; 2984-7.

# OCT Defined Underlying Plaque in ACS



Jia H, et al. JACC 2013;62:1748-58. Niccoli G et al. EHJ 2015; 36:1377-84. Wang L et al. EHJ 2015  
 doi:10.1093/ehjc.jev105 Higuma T et al. JACC Interv 2015;8:1166-76. Saia JACC Img 2015; 8: 566-75.

# Difference of Morphology





Plaque Rupture



No Rupture

Prevalence






Jia H, et al. JACC 2013;62:1748-58. Niccoli G et al. EHJ 2015; 36:1377-84. Wang L et al. EHJ 2015; 36:1377-84. Higuma T et al. JACC Interv 2015;8:1166-76. Saia JACC Img 2015; 8: 566-75.

# MGH Multicenter OCT Registry (n=126)




	Plaque Rupture (n=55)	OCT-Erosion (n=39)	OCT-Calcified Nodule (n=10)
Age	60.6	53.8	65.1
Male	80%	82%	80%
<b>STEMI</b>	<b>71%</b>	<b>39%</b>	<b>0%</b>
Lipidic plaque	100%	44%	0%
TCFA	67%	10%	0%
Fibrous cap thickness	60.4 $\mu$ m	169 $\mu$ m	NA




# Calcified Nodule




Virmani R et al. J Am Coll Cardiol 18;47:C13-8.



## Prevalence of calcified nodule in all lesions



## Prevalence of calcified nodule in ACS lesions




# ADAPT-DES VH-IVUS Comparison

	STEMI (n=167)	NSTEMI /UAP (n=217)	Stable CAD (n=292)	P-Value
Plaque Rupture	56%	36%	24%	<0.0001
VH-TCFA	65%	53%	44%	<0.0001
Ca-ThCFA	10%	19%	26%	<0.0001
Minimum lumen area (mm <sup>2</sup> )	2.5±0.7	2.8±1.0	3.0±1.1	<0.0001
Plaque Burden at MLA (%)	80.3±12.3	76.5±10.1	74.0±10.5	<0.0001
Remodeling index	1.11±0.47	1.02±0.36	0.99±0.41	0.0002

# Plaque morphology associated to STEMI


## With Plaque Rupture

Plaque Burden per 10%  
Odds Ratio: 2.8 [1.6, 4.8]  
 $p=0.0001$




## Without Plaque Rupture


MLA per 1.0 mm<sup>2</sup>  
Odds Ratio: 0.64 [0.44, 0.94]  
 $p=0.022$




## Large rupture with large thrombus



## Erosion with small thrombus




## Severe stenosis with small thrombus with rupture or erosion






# Culprit/Non-culprit Lesion Characteristics


## UAP



## NSTEMI




## STEMI



Madder RD, Erlige, JACC Interv 2013, Cather Cardiovasc Interv 2015, Euro Atheroscl Soc 2013



# Prevalence of Lipid Rich Plaque in Culprit Lesions



maxLCBI <sub>4mm</sub>	UAP	NSTEMI	STEMI
Culprit lesion	381 ± 239	448 ± 229	
Non-culprit lesion	146 ± 175	132 ± 154	
Cut off of Culprit lesion	208	317	400
AUC for cut off	0.87 (0.80-0.94)	0.79 (0.70-0.87)	0.93

Madder RD, Erlige, JACC Interv 2013, Cather Cardiovasc Interv 2015, Euro Atheroscl Soc 2013


# Relationship between the extent of lipid-rich plaque and clinical presentation in COLOR registry (n=800)

	MI (N=130)	Unstable AP (N=339)	Stable CAD (N=331)	P-value
Age, years	60 (54, 67)	65 (58, 73)	65(59, 71)	< 0.001
Male	78.9%	73.9%	82.2%	0.046
Hypertension	81.5%	91.0%	91.6%	0.01
Diabetes	30.6%	37.0%	39.3%	0.28
Dyslipidemia	80.2%	92.9%	94.3%	< 0.001
Prior PCI	33.9%	55.0%	43.0%	< 0.001
Lesion length, mm	24 (18, 30)	24 (18, 31)	24 (18, 34)	0.66
Plaque burden at MLA site, %	78.9 (72.5, 84.2)	75.4 (68.7, 82.0)	75.3 (67.0, 81.8)	0.18
LRP burden at MLA, %	35.0 (14.7, 49.1)	18.1 (0.0, 38.5)	26.0 (0.0, 47.9)	0.06
LCBI in lesion	141 (65, 247)	93 (29, 171)	98 (41, 185)	< 0.001
MaxLCBI <sub>4mm</sub>	392 (205, 661)	288 (96, 478)	305 (138, 495)	0.001

# Differences in Temporal Changes of Non-Culprit Lesions





## Stable Angina

## STEMI (100%)



# Unadjusted Long-term Outcome

Patient with NSTEMI-ACS are older, more female, more risk factors, prior MI, and diffuse coronary artery disease compared to those with STEMI.



Hirsh A, et al. Am J Cardiol. 2009 104: 333-7. Chan MY, et al. Circulation. 2009 119:3110-7. Darling CE, et al. Clinical Epidemiology 2013 5: 229-36. Vora AN, et al. Circ Cardiovasc QO 2016; 9:513-22

# Summary

- 1. STEMI culprit lesions have more plaque rupture with more necrotic core (plaque burden), and smaller lumen area compared to those in NSTEMI-ACS or stable culprit lesions.**
- 2. Non-rupture culprit lesions (erosion, calcified nodule) are more prevalent in NSTEMI-ACS or stable angina patients compared to STEMI pts.**
- 3. ACS non-culprit lesions have more unstable than non-culprit lesions in stable patients and some lesions remain unstable.**
- 4. In overall cohort (unadjusted cohort), NSTEMI-ACS patients showed worse outcome after discharge due to more risk factors and diffuse disease.**